Evercore ISI Group Rates PROCEPT BioRobotics (PRCT) buy

Evercore ISI Group reiterated its 'buy' rating for PROCEPT BioRobotics with a price target of $30, a 39.60% upside from the current price.

By EarningsIQ Research Desk · Published Jun 24, 2026, 7:02 AM EDT · Updated Jun 26, 2026, 11:03 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Evercore ISI Group rated PROCEPT BioRobotics Corporation ($PRCT) "buy" with a $30 price target on June 24, 2026.

Since the rating, $PRCT is up 12.6% after 1 week, down 19.9% after 1 month and down 15.7% to date (from the $20.85 close on Jun 24, 2026).

PRCT PROCEPT BioRobotics Corporation

$17.57 -42.88% year to date

Daily close · Oct 16, 2026

Key Points

Evercore ISI Group reiterated its 'buy' rating for PROCEPT BioRobotics (PRCT) with a $30 price target on June 24, 2026.
Evercore ISI Group's $30 price target implies 39.60% upside from PROCEPT BioRobotics Corporation's ($PRCT) current $21.49 share price.
Shares of NasdaqGM:PRCT traded near $20.6 on Wednesday, with a market cap of about $1.2 billion and a 52-week range of $19.35 to $62.17.
Recent insider buying activity included several executives purchasing shares on June 9, 2026, as detailed in the latest filings.

Get $PRCT trade alerts by text

We text you when insiders, Congress or big funds trade $PRCT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated PROCEPT BioRobotics Corporation alert may contain errors. Disclosures

Evercore ISI Group has reiterated its 'buy' rating on PROCEPT BioRobotics Corporation (NasdaqGM:PRCT) with a price target of $30. The announcement was made on June 24, 2026, by analyst Vijay Kumar.

Analyst rating track record

Evercore ISI Group vs. the S&P 500

YTD return +13.98% hypothetical

All-time return +27.04% S&P 500 +26.20%

vs. S&P 500 +0.84% ahead of the index

Hypothetical returns from Evercore ISI Group's disclosed trades, not real profit or advice. How we model this.

PROCEPT BioRobotics Corporation Stock Up 11.3%

Shares of PROCEPT BioRobotics traded around $20.6 on Wednesday. The company, which specializes in medical devices for urology, has a market capitalization of approximately $1.2 billion. Its stock has seen a 52-week low of $19.35 and a high of $62.17. The firm has a forward P/E ratio of -24.3 and a beta of 0.847. Key financial health indicators include a current ratio of 6.73 and a quick ratio of 5.38.

12-month forecast

$PRCT price target

PROCEPT BioRobotics Corporation daily closes and this analyst's $30 target. Not advice.

Recent Earnings

PROCEPT BioRobotics reported revenue of $322 million with a growth rate of 20.2%. Despite these positive revenue figures, the company is not yet profitable, posting a net margin of -31.8% and a return on equity of -27.8%. The next earnings report is expected on August 10, 2026.

Insider Buying and Selling at PROCEPT BioRobotics Corporation

In recent insider activity, several executives, including Desai Antal Rohit, Amy Dodrill, and Thomas Prescott, purchased shares on June 9, 2026. Each insider acquired shares at no disclosed cost, indicating potential confidence in the company's future.

Analysts Set New Price Targets

On June 24, 2026, Evercore ISI Group reiterated its 'buy' rating for PROCEPT BioRobotics with a $30 price target. Earlier, on June 11, 2026, Leerink Partners downgraded the stock to 'hold' with a $29 target. Piper Sandler also reiterated a 'buy' rating with a $35 target on April 30, 2026. The consensus among nine analysts is a 'buy' rating with an average price target of $30.22.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, headquartered in San Jose, California, is a healthcare company focused on developing surgical robotics solutions for urology. Its flagship product, the AquaBeam Robotic System, is used for minimally invasive urologic surgery, particularly for treating benign prostatic hyperplasia. The company, led by CEO Larry L. Wood, employs 888 people and continues to innovate in the medical devices industry.

Bottom Line

Evercore ISI Group's reaffirmation of its 'buy' rating for PROCEPT BioRobotics underscores continued confidence in the company's prospects. Investors track these analyst ratings closely, although it's important to remember that such recommendations are based on past data and market conditions. As always, 13F filings and analyst reports provide a snapshot of institutional sentiment and are not indicative of future performance.